| HOME >> BIOLOGY >> TECHNOLOGY |
BERKELEY HEIGHTS, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has been notified by the Listing Qualifications Staff of The NASDAQ Stock Market that it no longer complies with NASDAQ Marketplace Rule 4450(a)(5), which requires a minimum closing bid price of $1.00 per share. In accordance with Marketplace Rule 4450(e)(2), the Company has until June 16, 2008 to regain compliance, which requires a closing bid price of the Company's common stock at or above $1.00 per share for a minimum of 10 consecutive business days. In the event the Company does not regain compliance within this period, the Company may appeal a delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, and the Company's securities would remain listed pending the Panel's decision.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for the
treatment of patients with cancer. Two major programs anchor the Company's
research platform: DNA/RNA-based Medicines and Small Molecules.
Genasense(R) (oblimersen sodium) Injection is the Company's lead compound
from its DNA/RNA Medicines program. Genta is currently recruiting patients
to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with
advanced melanoma. The leading drug in Genta's Small Molecule program is
Ganite(R) (gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of symptomatic patients with
cancer-related hypercalcemia that is resistant to hydration. The Company
has developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered clinical
'/>"/>
| SOURCE Genta Incorporated Copyright©2007 PR Newswire. All rights reserved |